EurekaMag.com logo
+ Translate

Electrophysiologic and biochemical studies on the putative calcium channel blocker mdl 12330a in an endocrine cell


, : Electrophysiologic and biochemical studies on the putative calcium channel blocker mdl 12330a in an endocrine cell. Journal of Pharmacology & Experimental Therapeutics 243(1): 402-407

MDL 12,330A is a molecule structurally unrelated to other organic Ca++ channel ligands that may alter Ca++ channel function. Using whole cell patch clamp, [3H]PN200-110 binding and 45Ca++ uptake studies, we examined the effects of this compound on voltage-dependent Ca++ channels in rat anterior pituitary cells. At a concentration of 10-5Ca++ uptake studies, we examined the effects of this compound on voltage-dependent Ca++ channels in rat anterior pituitary cells. At a concentration of 10-5 M, MDL 12,330A showed little effect on outward K+ current, Na+ current or low-threshold Ca++ current in this cell line. At 10-6 M, MDL12, 330A reversibly inhibited slow Ca++ current in a voltage-dependent manner. 45Ca++ uptake was also blocked by this compound at 10-6 M, whereas [3H]PN200-110 binding was stimulant concentrations of 10-7 to 10-6 M. The results are consistent with an interaction of MDL 12,330A with slow Ca++ channels at a site allosterically linked to the 1,4-dihydropyridine binding site.

(PDF 0-2 workdays service)

Accession: 005349241

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Rampe, D.; Triggle, D.J.; Brown, A.M., 1987: Electrophysiologic and biochemical studies on the putative Ca++ channel blocker MDL 12,330A in an endocrine cell. MDL 12,330A is a molecule structurally unrelated to other organic Ca++ channel ligands that may alter Ca++ channel function. Using whole cell patch clamp, [3H]PN200-110 binding and 45Ca++ uptake studies, we examined the effects of this compound on...

Rampe D.; Brown A.M., 1987: Electrophysiological and biochemical studies on the putative calcium channel antagonist mdl 12330a. Federation Proceedings 46(3): 394

Dunlap, E.D.; Plowden, J.S.; Lathrop, D.A.; Millard, R.W., 1989: Hemodynamic and electrophysiologic effects of amlodipine, a new calcium channel blocker. The effects of amlodipine (300 micrograms/kg administered intravenously), a new, long-acting, dihydropyridine class, calcium channel blocking drug, were studied in atrially paced (120 beats/min), autonomically blocked dogs. Hemodynamic and electro...

Vetrovec G.; Dailey S.; Kay G.; Epstein A.; Plum V., 1989: Hemodynamic and electrophysiologic effects of amlodipine a new long acting calcium channel blocker. European Heart Journal 10(ABSTR SUPPL): 37

Geibel A.; Zehender M.; Hohnloser S.; Meinertz T.; Just H., 1989: Bepridil electrophysiologic and arrhythmogenic profile of a new calcium channel blocker used in the treatment of hypertension. Hypertension (Dallas) 13(5): 536

Daikuhara, H.; Kikuchi, F.; Ishida, T., 2013: The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study. Angiotensin II receptor blockers (ARB) are often co-administered with a calcium channel blocker (CCB) for treating hypertension. In this open-label randomised study, untreated diabetic hypertensive patients were randomised to receive either olmesa...

Matsui, Y.; O'Rourke, M.F.; Hoshide, S.; Ishikawa, J.; Shimada, K.; Kario, K., 2012: Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Day-by-day home blood pressure (BP) variability (BPV) was reported to be associated with increased cardiovascular risk. We aimed to test the hypothesis that the angiotensin II receptor blocker/calcium-channel blocker combination decreases day-by-d...

Garcia M.L.; King V.F.; Kaczorowski G.J., 1987: Interaction of kb 944 and mdl 12330a with the calcium entry blocker receptor complex in cardiac sarcolemmal membrane vesicles. Federation Proceedings 46(6): 1984

Waldmeier, P.C.; Wicki, P.; Fröstl, W.; Bittiger, H.; Feldtrauer, J.J.; Baumann, P.A., 1995: Effects of the putative P-type calcium channel blocker, R,R-(-)-daurisoline on neurotransmitter release. The alkaloid and medicinal herb constituent, R,R-(-)-daurisoline, was originally reported to be a N-type Ca2+ channel blocker, but newer evidence indicates that it is a blocker of P-type Ca2+ channels. To clarify its specificity with respect to N-...

Jamerson, K.A.; Nwose, O.; Jean-Louis, L.; Schofield, L.; Purkayastha, D.; Baron, M., 2004: Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Background: The Seventh Report of the Joint National Committee (JNC 7) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends initial combination therapy for patients whose blood pressure (BP) is >20/10 mm Hg abov...